FDA 483 - Laboratorios Liconsa SAU - January 17, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Laboratorios Liconsa's bioanalytical facility in Azuqueca de Henares, Guadalajara, Spain, identified significant deficiencies in method validation and documentation practices. The firm failed to adequately determine the stability of stock solutions, include all tested analytical sequences in reports, and maintain complete documentation for method validation experiments. These issues indicate a lack of robust quality control and record-keeping for critical analytical processes.
ID · 4de04511-c656-441f-b0e6-ccf88827097b